Chimerix, Inc. (CMRX), a biopharmaceutical company, on Tuesday announced that the FDA has accepted its NDA for Dordaviprone or ONC201, proposed for the treatment of recurrent H3 K27M-mutant diffuse glioma. The FDA has granted the application Priority Review, with a target action date of August 18, 2025.
This filing marks a significant milestone for Chimerix in advancing the first treatment specifically targeting this rare and aggressive form of brain cancer.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.